Breast Cancer

Seven professional organizations came together to issue a new position statment on recommendations for treating patients with aromatase-inhibitor-related bone loss (AIBL).

A recent study indicates that the use of bilateral mastectomy to treat women with ductal carcinoma in situ is unnecessary.

A recent study evaluated the effect of red light on hair growth in women with breast cancer.

Second primary cancers that occur in pediatric, adolescent and young adult (AYA) patients are deadlier than those that occur in older patients.

The Paxman Scalp Cooling System has been granted FDA clearance to reduce hait loss in patients with breast cancer recieving chemotherapy.

An ongoing trial is evaluating the addition of PARP inhibitor velaparib to a chemotherapy combination, for patients with HER2-negative, germline BRCA-associated metastatic or locally advanced breast cancer.

With more patients diagnosed with breast cancer looking to contralateral prophylactic mastectomy, it is important that surgeons discuss this procedure in-depth so patients can better understand.

Language barriers can mean patients put off preventive screenings, and even treatment, for fear of being misunderstood by their healthcare providers.

Thought the incidence of breast cancer has decreased in many US racial/ethnic populations, the rate has increased in the Asian-American population.

Angie Meillier, RN, MS, CPPM, discusses the importance of shared decision making and patient understanding in breast cancer and throughout oncology.

Fewer people are dying from cancer than years ago, according to a recent study.

Expert Adam M. Brufsky, MD, PhD, discusses the considerations for bone-targeted agents denosumab and zoledronic acid (Zometa) in patients with breast cancer.

For patients with breast cancer on aromatase inhibitors, preventive sexual counseling can reduce sexual dysfunction, and it should be provided earlier in treatment, with support from providers.

A recent study evaluated how muscle mass can be used to predict which patients will experience toxicities from chemotherapy and to what extent.

The PARP inhibitor olaparib improved PFS when compared to standard chemotherapy in patients with BRCA-positive breast cancer, according to findings from the phase III OLYMPIAD trial.

The FDA has granted approval to ribociclib (Kisqali) for firstline treatment of HR+/HER2- breast cancer.

According to findings presented at the 2017 Miami Breast Cancer Conference, combination eribulin and pembrolizumab showed promising results for patients with metastatic triple-negative breast cancer (TNBC).

For patients who may be unable to afford access to scalp cooling systems for chemotherapy-induced hair loss, the nonprofit organization Hair to Stay can help with their grants.

A study recently found that patients treated for breast cancer may experience decisional regret about their fertility choices.

A recent study found that online cognitive behavioral therapy (CBT) intervention led to an improvement in sexual functioning for patients with breast cancer experiencing adverse effects.

A poor diet earlier in life could be linked to a greatest risk of breast cancer before menopause.

Adding pertuzumab to trastuzumab and chemotherapy reduced the risk of recurrence of invasive disease or death in patients with HER2-positive early breast cancer.

Breast cancer expert Carey Anders discusses treatment for breast cancer patients with brain metastases.

Expert Joyce O'Shaughnessy discusses current topics in breast cancer, particular the advances and future for triple-negative breast cancer (TNBC).

Leslie R. Schover, founder of the Will2Love online resources, discusses the sexual health and fertility issues that can come as a result of cancer treatment, and how these issues can be managed. Join us for our #CureConnect tweetchat, Tuesday 2/21, on this topic.

The recent phase III OLYMPIAD trial findings show improved progression-free survival from olaparib in patients with BRCA-positive, HER2-negative breast cancer.

A new study found that high breast density surpasses other risk factors for breast cancer.

The clinical benefits and safety profiles for ribociclib remained consistent when treating both younger and elderly patients with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer.

Oral adherence is a growing problem for patients with breast cancer.